retatrutide triple agonist glp-1 gip glucagon phase 3 2025 First data, a Triumph of Science! Lilly's triple agonist delivers up

Bone 2019;125:17885 153

This multi-receptor engagement makes Retatrutide relevant to in vitro studies examining weight loss and weight reduction mechanisms, type 2 diabetes pathophysiology, and coordinated metabolic signaling

Further studies are needed to determine how much of the benefit comes from weight loss versus the medication itself, Thompson noted

Retatrutide needs similar data to compete

Yu D, Zou M, Pan Q, Song Y, Li M, Zhang X, et al

Figure 7: Photograph of Leonard Thompson in 1930 together with (A) his medical record and (B) chart of his blood sugar levels from December 1921 to January 1922 (credit:Thomas Fisher Rare Book Library, University of Toronto)